MIR-181b promotes chemoresistance in breast cancer by regulating Bim expression

Oncology Reports

Volumn 35, Issue 2, 2016, Pages 683-690

  Zheng, Yabing ^a   Lv, Xiaoai ^b   Wang, Xiaojia ^a   Wang, Bei ^b   Shao, Xiying ^a   Huang, Yuan ^a   Shi, Lei ^a   Chen, Zhanhong ^a   Huang, Jian ^a   Huang, Ping ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

Bim; Breast cancer; DOX resistance; MIR 181b; T 47D R

Indexed keywords

BIM PROTEIN; CASPASE; DOXORUBICIN; MICRORNA; MICRORNA 181B; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; MEMBRANE PROTEIN; MIRN181 MICRORNA, HUMAN; ONCOPROTEIN;

3' UNTRANSLATED REGION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; BLOOD SAMPLING; BREAST CANCER; BREAST CANCER CELL LINE; BREAST METASTASIS; CANCER PATIENT; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RESISTANCE; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; BIOSYNTHESIS; BREAST TUMOR; CELL MOTION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; ONCOGENE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MEMBRANE PROTEINS; MICRORNAS; ONCOGENES; PROTO-ONCOGENE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 84954286903     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4417     Document Type: Article

References (39)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Weigelt B, Peterse JL and van 't Veer LJ: Breast cancer metastasis: Markers and models. Nat Rev Cancer 5: 591-602, 2005.
3. J erusalem G, Rorive A and Collignon J: Chemotherapy options for patients suffering from heavily pretreated metastatic breast cancer. Future Oncol 11: 1775-1789, 2015.
4. Nakamura S, Yagata H, Ohno S, Yamaguchi H, Iwata H, Tsunoda N, Ito Y, Tokudome N, Toi M, Kuroi K, et al: Multicenter study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer 17: 199-204, 2010.
5. Yao YS, Qiu WS, Yao RY, Zhang Q, Zhuang LK, Zhou F, Sun LB and Yue L: miR-141 confers docetaxel chemoresistance of breast cancer cells via regulation of EIF4E expression. Oncol Rep 33: 2504-2512, 2015.
6. Xu F, Wang F, Yang T, Sheng Y, Zhong T and Chen Y: Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells. Cancer Cell Int 14: 538, 2014.
7. Shuhendler AJ, Prasad P, Zhang RX, Amini MA, Sun M, Liu PP, Bristow RG, Rauth AM and Wu XY: Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model. Mol Pharm 11: 2659-2674, 2014.
8. Mohell N, Alfredsson J, Fransson Å, Uustalu M, Byström S, Gullbo J, Hallberg A, Bykov VJ, Björklund U and Wiman KG: APR-246 overcomes resistance to DOX and doxorubicin in ovarian cancer cells. Cell Death Dis 6: e1794, 2015.
9. Gao JH, Chen FH, Wang L, Wei H and Meng SL: YM155 inhibits tumor growth and enhances chemosensitivity to cisplatin in osteosarcoma. Eur Rev Med Pharmacol Sci 19: 2062-2069, 2015.
10. Ambros V: The functions of animal microRNAs. Nature 431: 350-355, 2004.
11. Sevignani C, Calin GA, Siracusa LD and Croce CM: Mammalian microRNAs: A small world for fine-tuning gene expression. Mamm Genome 17: 189-202, 2006.
12. Ambros V: MicroRNA pathways in flies and worms: Growth, death, fat, stress, and timing. Cell 113: 673-676, 2003.
13. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, et al: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101: 2999-3004, 2004.
14. Qiu F, Xiong JP, Deng J and Xiang XJ: TRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185. Int J Clin Exp Pathol 8: 5053-5061, 2015.
15. Tian X, Xu L and Wang P: MiR-191 inhibits TNF-induced apoptosis of ovarian endometriosis and endometrioid carcinoma cells by targeting DAPK1. Int J Clin Exp Pathol 8: 4933-4942, 2015.
16. Toraih EA, Mohammed EA, Farrag S, Ramsis N and Hosny S: Pilot study of serum nicroRNA-21 as a diagnostic and prognostic biomarker in Egyptian breast cancer patients. Mol Diagn Ther 19: 179-190, 2015.
17. Kaboli PJ, Rahmat A, Ismail P and Ling KH: MicroRNA-based therapy and breast cancer: A comprehensive review of novel therapeutic strategies from diagnosis to treatment. Pharmacol Res 97: 104-121, 2015.
18. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-CT method. Methods 25: 402-408, 2001.
19. Czeczuga-Semeniuk E, Bielawski T, Lemancewicz D, Rusak M and Woczyski S: Vitamin A family compounds, estradiol, and docetaxel in proliferation, apoptosis and immunocytochemical profile of human ovary endometrioid cancer cell line CRL-11731. Folia Histochem Cytobiol 47: S127-S135, 2009.
20. Prathapan A, Vineetha VP and Raghu KG: Protective effect of Boerhaavia diffusa L. against mitochondrial dysfunction in angiotensin II induced hypertrophy in H9c2 cardiomyoblast cells. PLoS One 9: e96220, 2014.
21. Zahedifard M, Faraj FL, Paydar M, Yeng Looi C, Hajrezaei M, Hasanpourghadi M, Kamalidehghan B, Abdul Majid N, Mohd Ali H and Ameen Abdulla M: Synthesis, characterization and apoptotic activity of quinazolinone Schiff base derivatives toward MCF-7 cells via intrinsic and extrinsic apoptosis pathways. Sci Rep 5: 11544, 2015.
22. Frank DO, Dengjel J, Wilfling F, Kozjak-Pavlovic V, Häcker G and Weber A: The pro-apoptotic BH3-only protein Bim interacts with components of the translocase of the outer mitochondrial membrane (TOM). PLoS One 10: e0123341, 2015.
23. Geserick P, Wang J, Feoktistova M and Leverkus M: The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin. Cell Death Dis 5: e1412, 2014.
24. Wang B, Hsu SH, Majumder S, Kutay H, Huang W, Jacob ST and Ghoshal K: TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 29: 1787-1797, 2010.
25. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX and Shao JY: MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 14: 2348-2360, 2008.
26. Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, Yamamoto M and Ju J: Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics Proteomics 3: 317-324, 2006.
27. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ and Schmittgen TD: Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 120: 1046-1054, 2007.
28. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S and Majumder S: MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283: 29897-29903, 2008.
29. Giunti L, da Ros M, Vinci S, Gelmini S, Iorio AL, Buccoliero AM, Cardellicchio S, Castiglione F, Genitori L, de Martino M, et al: Anti-miR21 oligonucleotide enhances chemosensitivity of T98G cell line to doxorubicin by inducing apoptosis. Am J Cancer Res 5: 231-242, 2015.
30. J iang C, Long J, Liu B, Xie X and Kuang M: Mcl-1 Is a novel target of miR-26b that is associated with the apoptosis induced by TRAIL in HCC cells. Biomed Res Int 2015: 572738, 2015.
31. Yin W, Nie Y, Zhang Z, Xie L and He X: miR-193b acts as a cisplatin sensitizer via the caspase-3-dependent pathway in HCC chemotherapy. Oncol Rep 34: 368-374, 2015.
32. Kivits RA and Furneaux C: BIM: Enabling sustainability and asset management through knowledge management. ScientificWorldJournal 2013: 983721, 2013.
33. Youle RJ and Strasser A: The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59, 2008.
34. O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams J M, Cory S and Huang DC: Bim: A novel member of the Bcl-2 family that promotes apoptosis. EMBO J 17: 384-395, 1998.
35. Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E, Incio J, Digumarthy SR, Pollack SF, Song Y, et al: BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov 1: 352-365, 2011.
36. Shao YY, Chang YL, Huang CY, Hsu CH and Cheng AL: The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma. Oncology 85: 312-316, 2013.
37. Lee JH, Lin YL, Hsu WH, Chen HY, Chang YC, Yu CJ, Shih J Y, Lin CC, Chen KY, Ho CC, et al: Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer. J Thorac Oncol 9: 1385-1392, 2014.
38. Weber K, Harper N, Schwabe J and Cohen GM: BIM-mediated membrane insertion of the BAK pore domain is an essential requirement for apoptosis. Cell Reports 5: 409-420, 2013.
39. Park C, Hong SH, Kim GY and Choi YH: So-Cheong-Ryong-Tang induces apoptosis through activation of the intrinsic and extrinsic apoptosis pathways, and inhibition of the PI3K/Akt signaling pathway in non-small-cell lung cancer A549 cells. BMC Complement Altern Med 15: 113, 2015.